The Funding Trail

Part I of this series followed the federal money downstream — from the Treasury into hospital coffers through the CARES Act and the New COVID-19 Treatments Add-on Payment, and into patients' bodies as remdesivir administered without consent. Part II follows the same federal money in the opposite direction. Upstream. Back through the National Institutes of Health, through a midtown Manhattan nonprofit called EcoHealth Alliance, into a research collaboration with the Wuhan Institute of Virology that the U.S. government would, four years after the pandemic began, formally determine had violated the terms of its federal grant.

The story of the EcoHealth grant is documented in places most readers have never visited. The NIH RePORTER public grant database. The Federal Register. The HHS Action Referral Memorandum of May 2024. The Senate HELP Committee Minority Oversight Report. The House Select Subcommittee on the Coronavirus Pandemic Final Report. The transcripts of two Senate exchanges between Senator Rand Paul and Anthony Fauci in 2021. A letter on NIH letterhead, signed by NIH Principal Deputy Director Lawrence Tabak, dated October 20, 2021.

These documents are not contested. They are not the work of partisan think tanks or independent investigators with access only to leaked materials. They are official records of the United States government, produced by the institutions whose conduct they describe. What they establish, read together, is a pattern of federal funding that flowed to the Wuhan Institute of Virology under the umbrella of routine zoonotic-disease surveillance, that crossed into research the federal government had specifically restricted, that was reported back to NIAID in ways the agency itself later acknowledged were inadequate, and that became — by May of 2024 — the basis for one of the most significant federal research-debarment actions of the past decade.

This is the documentary record of how that happened.

---

The Grant That Was Supposed to Be Routine

The grant at the center of this story is identified, in the federal record-keeping system, by the alphanumeric designation R01AI110964. It is publicly searchable, in full, in the National Institutes of Health's RePORTER database. Anyone with an internet connection can read its abstract, its funding history, and its listed publications.

The grant was titled "Understanding the Risk of Bat Coronavirus Emergence." Its principal investigator was Peter Daszak, the British-born president of EcoHealth Alliance, a New York-based nonprofit that had built its institutional identity around the field of disease ecology — the study of how zoonotic pathogens move between animal reservoirs and human populations. Its funding agency was the National Institute of Allergy and Infectious Diseases, the largest single component of the NIH and, throughout the period covered by this grant, under the directorship of Anthony Fauci.

The grant was first awarded in 2014. It was renewed in 2019 for an additional five-year term. The total federal funding obligated across both award periods was approximately $3.7 million. By the standards of NIH research grants, this was a modest sum. It was not, on its face, an unusual award. NIAID funds zoonotic-disease surveillance work in many countries. Bat coronavirus surveillance, in particular, had been an area of growing institutional interest since the SARS outbreak of 2002 and 2003 demonstrated that bat-origin coronaviruses could produce human pandemics.

The grant's stated purpose, as set forth in its public abstract, was to identify and characterize coronaviruses circulating in bat populations in southern China — the same geographic region that had produced SARS — and to assess their potential for spillover into human populations. The work involved fieldwork in caves and rural areas, sampling of bat guano and bat blood, sequencing of viral genomes, and laboratory analysis of the resulting viruses to characterize their biological properties.

None of this, in 2014, was unusual. What was unusual — and what would become the documentary spine of this article — was the structure under which the laboratory work was conducted. Because EcoHealth Alliance did not, itself, possess the laboratory facilities or the technical expertise required to characterize bat coronaviruses at the level of detail the grant proposed. For that work, EcoHealth subcontracted a portion of the grant funds to a foreign research institution. That institution was the Wuhan Institute of Virology, the highest-level virology research facility in the People's Republic of China. The principal Chinese collaborator on the subaward was Shi Zhengli, the WIV scientist who had built her professional reputation on bat coronavirus research and who, by 2014, was internationally regarded as one of the leading researchers in the field.

The structure was not, by itself, unlawful. NIH grants routinely subaward portions of work to foreign collaborators. The federal regulatory framework governing such subawards — including the 2 CFR Part 200 Uniform Guidance — sets out specific requirements about disclosure, oversight, biosafety, and reporting. Whether those requirements were honored in the case of the WIV subaward is the documentary question that runs through every section that follows.

---

The Pause and the Workaround

On October 17, 2014 — approximately four months after the original R01AI110964 grant was awarded — the White House Office of Science and Technology Policy issued a statement that would, in retrospect, define the regulatory landscape across which the grant operated for the next three years. The statement was titled "U.S. Government Gain-of-Function Deliberative Process and Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS, and SARS Viruses."

The statement announced that, effective immediately, federal funding agencies would suspend new funding for "selected gain-of-function research projects that may be reasonably anticipated to confer attributes to influenza, MERS, or SARS viruses such that the resulting virus would have enhanced pathogenicity and/or transmissibility in mammals via the respiratory route." The pause also urged researchers receiving existing federal funding for such work to voluntarily suspend ongoing experiments pending a federal risk-benefit deliberation.

The 2014 pause is, in the regulatory record, the moment when the federal government formally acknowledged that certain categories of laboratory research on respiratory pathogens raised public-health concerns sufficient to warrant a funding suspension. The statement's language is precise. It identifies "influenza, MERS, and SARS viruses" — the three categories of respiratory pathogens for which, at the time, the technical capacity to construct chimeric or otherwise enhanced versions had been demonstrated in published research. It identifies "enhanced pathogenicity and/or transmissibility in mammals via the respiratory route" as the specific functional concern.

SARS, in 2014, meant SARS-related coronaviruses. The category was not narrowly limited to the specific 2003 SARS-CoV-1 strain. It encompassed the broader phylogenetic clade of SARS-related betacoronaviruses, including the bat-origin viruses that EcoHealth Alliance was, by the terms of grant R01AI110964, sampling and characterizing in collaboration with the Wuhan Institute of Virology.

The continuation through the pause

The R01AI110964 grant did not stop in October 2014. It continued through the federal pause. According to the NIH RePORTER record, funding obligations under the grant were made in fiscal years 2015, 2016, and 2017 — the period during which the federal moratorium was in effect. Whether any of the work funded under the grant during this period fell within the scope of the 2014 pause language was a determination the funding agency itself was responsible for making.

NIAID's documented position throughout this period was that the work funded under the grant did not constitute the kind of gain-of-function research the pause was intended to address. Critics within the scientific community — including senior virologists associated with the Cambridge Working Group, an organization formed in 2014 specifically to advocate for stricter oversight of high-risk pathogen research — disputed this characterization. The dispute was not a minor disagreement at the margins of policy. It went to the substantive question of whether the federal pause functioned as a meaningful regulatory mechanism or as a formality that could be navigated by sufficiently sophisticated grantees and their funding-agency interlocutors.

The lifting and the P3CO framework

On December 19, 2017, the U.S. Department of Health and Human Services lifted the 2014 pause. The lifting came with a new regulatory framework, denominated the P3CO Framework — for "Potential Pandemic Pathogen Care and Oversight." The P3CO framework was meant to replace the blanket pause with a structured review process under which proposed research involving potential pandemic pathogens would be reviewed by a designated HHS committee for consideration of biosafety and biosecurity concerns.

The P3CO framework, as it operated from 2018 forward, has been the subject of substantial documentary review by Congressional oversight bodies. The framework's central feature was that proposed research projects falling within its scope would be referred by funding agencies to an interdepartmental review committee, which would assess the public-health risks of the proposed work and either approve it, modify the conditions of its funding, or decline to support it.

Whether grant R01AI110964 — and specifically the work conducted under the WIV subaward — was referred to the P3CO review committee is a matter of documentary record. According to the Senate HELP Committee Minority Oversight Report and the House Select Subcommittee on the Coronavirus Pandemic Final Report, the EcoHealth grant was not referred for P3CO review. NIAID's stated position was that the proposed work did not meet the threshold for P3CO referral. Critics — including senior virologists with no apparent partisan affiliation, such as Rutgers University's Richard Ebright — have argued that this determination was inconsistent with the scope of the work as it was actually conducted at WIV.

The structural significance of the non-referral is substantial. The federal regulatory framework that was, on paper, designed to provide independent biosafety and biosecurity oversight of potential pandemic pathogen research did not function for the grant most directly implicated in the subsequent pandemic. The agency responsible for making the referral determination was the same agency funding the research. The conflict of institutional position is documentary.

---

The Lancet Statement

On February 19, 2020 — at a moment when the international scientific community was still in the early stages of attempting to characterize the novel coronavirus that had emerged in Wuhan — The Lancet published a letter signed by twenty-seven scientists titled "Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19." The letter declared its signatories' opposition to "conspiracy theories suggesting that COVID-19 does not have a natural origin." It asserted, without qualification, that scientific evidence "overwhelmingly conclude[d]" that the virus had emerged through natural zoonotic transmission.

The letter's organizer was Peter Daszak.

This fact was not disclosed in the original publication. Readers of the letter — including, plausibly, every public-health official, journalist, and policy-maker who would, over the following two years, cite the letter as evidence of scientific consensus — were not told that its principal organizer was the principal investigator of the federal grant whose subaward to the Wuhan Institute of Virology was the most directly relevant funding relationship to the question the letter purported to settle.

The orchestration of the letter has since been documented in detail through Freedom of Information Act releases obtained by U.S. Right to Know, a non-partisan transparency organization. The released emails establish that Daszak organized the signatories, drafted significant portions of the text, and made a deliberate decision — communicated explicitly in correspondence — that the letter should be made to appear as having originated independently of EcoHealth Alliance.

One email in the FOIA release, sent by Daszak to a colleague during the drafting period, reads in operative part: "We'll then put it out in a way that doesn't link it back to our collaboration so we maximize an independent voice."

The retroactive disclosure

In June 2021, sixteen months after the original publication, The Lancet published an addendum to the February 2020 letter, acknowledging that several signatories — including Daszak — had financial relationships with EcoHealth Alliance and the Wuhan Institute of Virology that should have been disclosed in the original publication. The addendum was, by any reasonable journalistic standard, an admission that the original letter had been published with an undisclosed conflict of interest at its center.

The 2023 Lancet COVID-19 Commission report, chaired by Columbia University economist Jeffrey Sachs, acknowledged the failure further. Sachs himself, in subsequent public commentary, has stated that the original Lancet letter "should have been considered scientific misconduct" given the undisclosed conflicts. Sachs's institutional position — the chair of the Commission established by The Lancet itself — gave his assessment particular documentary weight.

The strategic function of the February 2020 letter, in the early phase of the pandemic, is what made the conflict-of-interest failure consequential. The letter was cited, repeatedly, by public-health agencies, by social-media content moderation policies, by journalists evaluating contested claims about the virus's origin, and by federal officials making public statements about the state of scientific understanding. It was, for a critical period in early 2020, the document that provided institutional cover for the proposition that questioning the natural-origin hypothesis was inconsistent with mainstream science. That this document was orchestrated, with intentional concealment of its organizing source, by the principal investigator of the most directly implicated federal grant is not a minor footnote. It is the documentary record of how a contested scientific question was prematurely closed in the public discourse, by a person with a documented institutional stake in the closure.

---

The Proximal Origin Pivot

Two and a half weeks before the Lancet letter was published, on the morning of February 1, 2020, NIH Director Francis Collins and NIAID Director Anthony Fauci convened a conference call. The participants included Kristian Andersen of the Scripps Research Institute, Eddie Holmes of the University of Sydney, Robert Garry of Tulane University School of Medicine, Jeremy Farrar of the Wellcome Trust, and several other senior virologists. The agenda was to discuss the genomic features of the novel coronavirus that had emerged in Wuhan and to assess what those features indicated about the virus's origin.

The day before the conference call — January 31, 2020 — Andersen had emailed Fauci and Collins directly. His email, subsequently released through the House Select Subcommittee on the Coronavirus Pandemic, contained the following passage:

The unusual features of the virus make up a really small part of the genome (<0.1%) so one has to look really closely at all the sequences to see that some of the features (potentially) look engineered. . . . [The genome is] inconsistent with evolutionary theory.Kristian Andersen email to Anthony Fauci, January 31, 2020

Holmes's email contributions to the same period express comparable concerns. Garry's contributions describe the furin cleavage site at the boundary of the virus's S1 and S2 spike protein subunits as a feature whose evolutionary derivation was difficult to explain through natural processes alone. The substantive virological point under discussion was specific. The novel coronavirus possessed features — most notably the furin cleavage site — that were unusual within the broader family of bat coronaviruses and whose presence raised, at minimum, scientific questions that the participating virologists were taking seriously.

The February 1 conference call took place. Within four days of the call, the same scientists were drafting a paper. The paper was titled "The Proximal Origin of SARS-CoV-2." It was published on March 17, 2020 in Nature Medicine. Its conclusion was unqualified: "Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus."

The pivot — from privately retained doubts on January 31 to publicly published certainty on March 17 — is the documentary core of this section. Whether the privately retained doubts were resolved by additional analysis between February 1 and March 17, or whether they were suppressed in deference to institutional or political pressures, is a question that the public record now substantially answers.

The Slack messages

In July 2023, the House Select Subcommittee on the Coronavirus Pandemic released a tranche of internal communications among the Proximal Origin authors, obtained through the Subcommittee's investigative authority. The communications included Slack messages exchanged among Andersen, Holmes, Garry, and other participants in the drafting process during the period between the February 1 call and the paper's March 17 publication.

The Slack record establishes that the privately retained doubts did not resolve before publication. They were retained — and in some cases intensified — even as the published paper was being finalized. One Andersen Slack message, written during the drafting period, states in operative part: "I'm 60-40 lab." The message is a probability estimate. Andersen, in the period during which he was drafting and finalizing the published conclusion that the virus was not a laboratory construct, was assessing the lab-origin probability at sixty percent.

Other messages in the released record document additional retained doubts. The internal disagreement among the authors about whether the published conclusion was supportable was substantial. The published paper expressed none of it.

The institutional context

The Proximal Origin paper was, between March 2020 and the release of the FOIA emails and the Subcommittee Slack records, the principal scientific reference cited in support of the proposition that the lab-origin hypothesis was inconsistent with the genomic evidence. It was cited in public-health agency communications, in social-media platform content moderation policies, and in reporting by major news organizations. Its institutional weight derived from its publication in Nature Medicine — one of the most prestigious journals in the biomedical sciences — and from the senior credentials of its authors.

What the documentary record now establishes is that the paper was conceived in the immediate aftermath of a conference call convened by the NIH Director and the NIAID Director, was drafted in a period during which its authors retained substantial private doubts about its conclusion, and was published with institutional confidence that those private doubts did not warrant qualification of the public conclusion. The relationship between the conference call and the paper, and the question of whether the conference call influenced the paper's published conclusions, is a documentary question that remains, in May 2026, a subject of ongoing investigation.

---

The Congressional Record

Two Senate hearings, two clear exchanges, one documentary contradiction.

May 11, 2021

Senator Rand Paul, M.D., questions Anthony Fauci before the Senate Health, Education, Labor and Pensions Committee. The exchange concerns whether NIH funded gain-of-function research at the Wuhan Institute of Virology.

July 20, 2021

Two months later, the same committee. Paul returns to the question, citing specific published research conducted at WIV with NIH funding. Fauci's denial is reiterated in essentially identical terms.

October 20, 2021

Three months after the second denial, NIH Principal Deputy Director Lawrence Tabak sends a letter to Representative James Comer, then ranking member of the House Committee on Oversight and Reform. The letter is on NIH letterhead. Its operative passage reads as follows.

EcoHealth Alliance, Inc. did include this requirement in its sub-award to WIV. As sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do. Regardless, the grantee has now submitted the [Year Five] progress report to NIH. The NIH is examining the report and will determine whether additional acts need to be taken. . . . [In the experiments] humanized mice infected with the SHC014 WIV1 bat coronavirus became sicker than those infected with the WIV1 bat coronavirus.Letter from NIH Principal Deputy Director Lawrence A. Tabak to Representative James Comer, October 20, 2021

Translated from regulatory prose: NIH's own Principal Deputy Director, in writing, on official letterhead, acknowledged that the EcoHealth grant had funded experiments in which chimeric bat coronaviruses produced more severe disease in humanized mice than the parent strain. The Tabak letter further acknowledged that EcoHealth had been required to report this result to NIH within two years of its occurrence — and had not done so within the required timeframe.

The substantive contradiction with the May and July testimony is documentary. Fauci had testified that NIH had not ever and does not now fund gain-of-function research at WIV. Three months later, NIH's Principal Deputy Director, in writing, acknowledged that NIH had funded research at WIV in which experimental chimeric viruses caused enhanced disease in mammalian models — the operative definition of gain-of-function research that the 2014 federal pause had been designed to address.

The defense and its limits

Fauci's documented defense, articulated repeatedly in subsequent public commentary and in his January 2024 fourteen-hour transcribed interview before the House Select Subcommittee on the Coronavirus Pandemic, has been that the research did not meet the formal NIH technical definition of "gain-of-function research of concern" under the P3CO framework. The argument is that the experiments described in the Tabak letter, while producing enhanced disease in mice, did not involve a pathogen that had been pre-determined to constitute a "potential pandemic pathogen" within the meaning of the P3CO framework's definitional language, and therefore did not require P3CO referral or fall within the scope of the public meaning of "gain-of-function research."

The defense is technically articulable. It has also been substantively challenged by senior virologists with documented credentials and no apparent partisan motivation. Richard Ebright of Rutgers University — a microbiologist whose published work on bacterial transcription is among the most cited in the field — has stated repeatedly, in testimony and in published commentary, that the experiments described in the Tabak letter meet the operational scientific definition of gain-of-function research, and that the technical-definitional argument advanced in defense of the May and July 2021 testimony is, in his assessment, "untrue."

The House Select Subcommittee's December 2024 final report concluded that the testimony pattern warranted further investigation by the Department of Justice for potential violations of 18 U.S.C. § 1001. No such criminal referral has, as of May 2026, resulted in formal charges. The five-year statute of limitations for false-statement violations under § 1001 closed for the May 11, 2021 testimony in May 2026. The window for the July 20, 2021 testimony closes in July 2026. Subsequent testimony — including the January 2024 transcribed interview — remains within the statutory window through January 2029.

This article does not assert that Fauci committed perjury. The formal determination of perjury requires either a criminal conviction or a finding by a court of competent jurisdiction. Neither exists. What this article asserts, and what the documentary record establishes, is that the testimony provided to the Senate in May and July of 2021 was inconsistent with NIH's own subsequent administrative acknowledgments, and that the House Select Subcommittee, after extensive investigation, concluded the inconsistency warranted further institutional inquiry that has not, to date, produced charges.

---

The Suspension and Proposed Debarment

Three years after the Tabak letter, on May 14, 2024, the suspension and proposed debarment of EcoHealth Alliance from federal funding became effective. On May 15, 2024, the HHS Suspension and Debarment Official issued the formal Notice letter to Peter Daszak, EcoHealth Alliance's president, accompanied by an Action Referral Memorandum dated the same day.

One week later, on May 21, 2024, a separate but related suspension and proposed debarment action took effect against Peter Daszak personally.

The action's scope and significance require careful description.

What the action was

The HHS action was a suspension combined with a proposed debarment — administrative actions that, in the federal funding context, constitute the most serious sanctions short of criminal prosecution that the executive branch can impose on a recipient of federal funds. The action was government-wide. It applied across the federal procurement system (governed by the Federal Acquisition Regulation) and the federal nonprocurement system (governed by 2 CFR Part 180), meaning that EcoHealth Alliance and Peter Daszak were rendered ineligible for federal contracts, grants, cooperative agreements, and any other federal funding mechanism. The action was published through SAM.gov, the federal government's centralized exclusion-listing system.

The action was not, at the time of the May 2024 notices, a final debarment. Under the federal debarment regulations, a suspension is an immediate temporary exclusion that may be imposed pending a debarment proceeding, and a proposed debarment initiates the formal proceeding under which the recipient may contest the proposed action and present evidence in mitigation. The progression from suspension and proposed debarment to final debarment, or to the dismissal of the proposed action, is a process that unfolds over months following the initial notice.

The grounds

The Action Referral Memorandum dated May 15, 2024 set out the grounds for the suspension and proposed debarment. They include, in summary form:

First, EcoHealth Alliance's documented failure to comply with the terms of its NIH grant, including failure to submit required progress reports within the timeframes specified by NIH. Second, EcoHealth Alliance's failure to disclose to NIH the results of certain experiments conducted under the WIV subaward — specifically, experiments that produced viruses with enhanced replication or pathogenicity properties that the grant terms required to be reported. Third, EcoHealth Alliance's inadequate biosafety oversight of the WIV subaward, including its inability to provide NIH with information about laboratory procedures, biosafety practices, and experimental records at the WIV facility. Fourth, EcoHealth Alliance's documented misrepresentations to NIH regarding the scope and nature of work conducted under the subaward.

The grounds, as articulated in the federal record, are not contested factual claims. They are formal administrative findings by the United States government, made by the agency whose funds were misused, after an extended internal review process and with the support of an Office of Inspector General audit.

The institutional significance

Federal debarment actions of this scope are unusual. The federal government does not typically debar large research-funding recipients except in cases of substantial documented misconduct. The combination of an organizational debarment and a parallel personal debarment of the principal investigator is rarer still. The May 2024 action against EcoHealth Alliance and Peter Daszak is, by any reasonable institutional measure, the federal government's formal acknowledgment that the funding relationship at the center of this article — the same funding relationship that had been the subject of the Lancet letter denying its relevance to pandemic origins, the conference call producing the Proximal Origin paper, and the May and July 2021 Senate testimony — was, in the end, a documented compliance failure of sufficient magnitude to warrant the most serious available administrative sanction.

The action was triggered, in significant part, by recommendations from the House Select Subcommittee on the Coronavirus Pandemic and by the findings of an HHS Office of Inspector General audit completed in 2023. The investigative bodies whose work produced the May 2024 debarment were the same bodies whose access to the documentary record had developed over the preceding three years through a combination of FOIA litigation, Congressional subpoenas, and inter-agency cooperation that the original grant administration had not made readily available.

---

The Origin Question and Why Part II Does Not Resolve It

This article does not advance a position on the origin of SARS-CoV-2. The reason is straightforward. The U.S. intelligence community itself remains divided on the question, and the divisions among institutional bodies of comparable credentialing make it inappropriate for an investigative journalist to declare a resolution that the intelligence community has not reached.

The documented institutional record, as of May 2026, establishes the following:

The Federal Bureau of Investigation assesses, with moderate confidence, that COVID-19 most likely emerged from a laboratory incident in Wuhan. FBI Director Christopher Wray made the position public in February 2023 in an interview with Fox News, and the FBI has held that institutional position since at least 2021.

The Department of Energy, drawing on the analytic resources of its national laboratory system, assesses with low confidence that a laboratory incident was the most likely origin. The DOE assessment was reported by the Wall Street Journal in February 2023 based on a classified intelligence community update circulated to senior policy-makers.

The Central Intelligence Agency, in an updated assessment released publicly in January 2025, concluded with low confidence that a research-related origin was more likely than a natural zoonotic origin. The updated CIA assessment marked a significant institutional movement; the agency had previously declined to assess origin probability.

Four other intelligence community elements assessed natural zoonotic spillover as more likely, in each case with low confidence. The Office of the Director of National Intelligence's declassified summary acknowledged that the intelligence community remained divided.

Beyond the intelligence community, both the Senate HELP Committee Minority Oversight Report and the House Select Subcommittee on the Coronavirus Pandemic Final Report concluded that a laboratory-related origin was the more likely explanation, based on documentary review and witness testimony rather than classified intelligence.

Congress in May 2023 passed, and the President signed, the COVID-19 Origin Act, requiring the declassification of intelligence concerning the origins of the pandemic. The declassification process under that Act has been ongoing.

What the divided intelligence community record establishes, for the purposes of this article, is that the lab-origin hypothesis — characterized as a "conspiracy theory" by the February 2020 Lancet letter that Peter Daszak orchestrated — is not, as of May 2026, a fringe position. It is the assessed position of multiple U.S. intelligence agencies, including the principal counter-intelligence agency of the United States, and of two Congressional investigative committees with substantial documentary records.

This Part does not undertake to resolve that institutional disagreement. The funding-and-disclosure pattern documented in Sections I through VI is structurally significant regardless of how the origin question is ultimately resolved. If a laboratory-related origin is eventually established, the documentary record of grant compliance failures, undisclosed conflicts in published statements, contradictions in Congressional testimony, and the documented suspension and proposed debarment becomes the documentary record of a failure of historic magnitude. If a natural-spillover origin is eventually established, the same documentary record establishes a pattern of oversight and disclosure failures that the federal regulatory framework has not addressed.

The documentary record of the funding architecture stands on its own. The intelligence community's assessment of pandemic origin, whatever it may eventually settle into, is the surrounding context within which the funding architecture's documented failures must be understood.

---

The Pattern

What Part I and Part II of this series establish, read together, is the structural shape of the pandemic-era federal scientific apparatus.

The same federal scientific agency — the National Institute of Allergy and Infectious Diseases — funded the upstream coronavirus research described in Sections I through VII of this article. The same agency sponsored the ACTT-1 trial that produced the FDA EUA evidence base for remdesivir, as documented in Part I. The same Director of that agency was the public face of pandemic policy throughout the period covered by both articles. The same Director provided the testimony to Congress about the agency's funding of upstream coronavirus research, and the same Director announced the trial results from the Oval Office that became the basis for the federal financial architecture incentivizing remdesivir administration in U.S. hospitals.

This is not, in itself, an argument that any single individual designed the system to produce the documented failures. It is the structural observation that when the same agency funds the upstream research, sponsors the downstream trial, drafts the protocol that becomes hospital practice, and designs the financial incentives that drive administration, the absence of independent checks at each stage is itself the failure.

Read down the column. The same agency. The same Director. The same institutional architecture. The funding of the research that some intelligence agencies assess produced the pandemic. The communication that closed the origin question prematurely in the public discourse. The trial that produced the regulatory authorization. The protocol that determined hospital practice. The testimony to Congress about all of it. And, four years later, the formal administrative finding that the upstream funding relationship had operated under documented compliance failures sufficient to warrant the most serious available federal sanction.

This is the structural shape. Whether it is the rational, predictable output of a system in which one agency was assigned too many functions without independent oversight at any stage — or whether it is something narrower and more deliberate — is a question that the documentary record does not, on its own, fully resolve. What the documentary record does establish is that the architecture, as it operated, did not contain the checks that the federal framework was supposed to provide.

---

The Accountability Question

What has happened. What has not.

The May 2024 suspension and proposed debarment of EcoHealth Alliance and Peter Daszak is real. It is recorded in SAM.gov. It is supported by an HHS Action Referral Memorandum and an Office of Inspector General audit. It is, by any institutional measure, a serious federal sanction. It is also, as a practical matter, limited. The successor entities and broader research ecosystem within which EcoHealth operated continue. Other federal grants to other organizations conducting comparable work continue. The structural framework — including the P3CO review process — that failed to function as intended for grant R01AI110964 has not been substantially reformed.

No criminal charges have been brought against any individual associated with the funding-and-testimony pattern documented in Sections I through VI. The five-year statute of limitations for false-statement violations under 18 U.S.C. § 1001 closed for the May 11, 2021 Senate testimony in May 2026. The window for the July 20, 2021 testimony closes in July 2026. Subsequent testimony, including the January 2024 transcribed interview before the House Select Subcommittee, remains within the statutory window through January 2029.

The False Claims Act framework remains potentially available for grant compliance fraud. Where a federal grant recipient submits false certifications of compliance with grant terms in connection with reimbursement claims, the structural elements of an FCA action are present. Whether qui tam relators with insider EcoHealth documentation will pursue this avenue depends, in part, on the Eleventh Circuit's pending review of Zafirov v. Florida Medical Associates and the broader doctrinal landscape after Loper Bright Enterprises v. Raimondo, the same doctrinal openings that govern the remdesivir litigation discussed in Part I of this series.

The reform of the federal biosafety and biosecurity oversight architecture, recommended by the Senate HELP Minority Oversight Report and by the House Select Subcommittee, has not occurred at the level the reports recommended. The institutional architecture that produced the compliance failures remains, in May 2026, structurally similar to the architecture that operated in 2020.

The accountability question, as it stands at the time of this article, is not whether the documented failures occurred. The institutional record establishes that they did. The question is whether the institutional response — the HHS suspension and proposed debarment, the Congressional reports, the FOIA releases — represents the conclusion of accountability or its preliminary stage.

The doctrinal openings described in Part I of this series — the post-Loper Bright framework for independent statutory construction, the Major Questions Doctrine, the False Claims Act framework conditional on lawful federal authorization — apply to grant-fraud and oversight-failure litigation with no less force than to remdesivir administration litigation. The same legal architecture that has begun to crack in PREP Act cases can, in principle, crack in grant-fraud cases. Whether the rest of the federal accountability system — Department of Justice, civil enforcement bodies, state attorneys general acting under state-level fraud statutes — operates on the documented record is, as of the writing of this article, an open question.

The next part of this series will examine the third agency in this architecture: the federal scientific establishment's relationship with the broader gain-of-function research enterprise, the policy debate that preceded and accompanied the 2014 pause and the 2017 P3CO framework, and the documented testimony pattern that has, in the assessment of multiple institutional bodies, departed from the documentary record at multiple points.

This part has established the funding trail. The next will establish what the funding produced.

What both establish, considered together, is that the question of accountability — like the question of consent in Part I — is not contested at the level of whether something happened. It is contested only at the level of whether the institutional system, as currently constructed, will respond to what happened with anything more than the partial sanctions and inconclusive reports that have, to date, constituted its response.

The documentary record speaks. The question is whether the institutions whose authority depends on that record will speak in turn.